Catching you up on the week of December 22–28, 2025: the trial milestones, regulatory moves, and business developments shaping psychedelic medicine right now.
AtaiBeckley Inc. (ATAI): AtaiBeckley added to the Nasdaq Biotechnology Index
AtaiBeckley announced its common stock was added to the Nasdaq Biotechnology Index (NBI), effective before the market open on December 22, 2025. The index inclusion — a milestone that typically broadens passive-fund ownership — capped a year in which the company raised roughly $300 million, completed the atai–Beckley Psytech combination, and advanced BPL-003, VLS-01 and EMP-01 in Phase 2 development.
Source: globenewswire.com
PharmAla Biotech Holdings Inc. (MDMA): PharmAla files U.S. registration statement with the SEC
PharmAla Biotech filed a registration statement with the U.S. Securities and Exchange Commission detailing a securities offering, part of a series of capital-markets moves that included an earlier base shelf prospectus and a Radium Capital loan facility against Australian R&D tax incentives. The filings aim to give the MDMA supplier financing flexibility as it scales commercial production.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.